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ABSTRACT 
ASSESSMENT OF A MARINE POLYSACCHARIDE FOR USE AS EXCIPIENT 






Pharmaceutical Hot Melt Extrusion (HME) is currently investigated by both industry and 
academia as a method for manufacturing solid oral dosages with improved bioavailability 
of poorly-water soluble active pharmaceutical ingredients (APIs) and control drug release 
of water-soluble APIs. Although HME is traditionally utilizing synthetic polymers to 
produce such dosages, biopolymers constantly gain ground by virtue of renewability, 
biocompatibility and in some cases biodegradability. In this work, the possibility of using 
Keltone, a marine polysaccharide derived from brown seaweed, as a polymeric excipient 
for pharmaceutical HME is explored. Keltone is insoluble in acidic pH and soluble in 
basic pH, therefore making it suitable for intestinal drug release. The processability of 
Keltone by extrusion using water and Eudragit EPO as plasticizers, and 
Diphenhydramine Hydrochloride and Clotrimazoleas as active pharmaceutical 
ingredients is assessed. The amount of residual water in the extrudates is determined by 
thermogravimetric analysis. The thermal transitions of the extrudates are determined by 
Differential Scanning Calorimetry. 
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CHAPTER 1  
INTRODUCTION 
1.1 Objective 
Pharmaceutical Hot-melt Extrusion (HME) is currently pursued by both industry and 
academia as a “green”, solvent-less process technology for manufacturing oral dosage 
formulations and medical devices in a continuous and controlled fashion (Crowley et al., 
2007). In this work, the possibility of using Keltone, a marine polysaccharide derived from 
brown seaweed, as a polymeric excipient for pharmaceutical HME was explored. Keltone is 
insoluble in acidic pH and soluble in basic pH, therefore making it suitable for intestinal 
drug release. The processability of Keltone by extrusion using water and Eudragit EPO as 
plasticizers, Diphenhydramine Hydrochloride and Clotrimazoleas active pharmaceutical 
ingredients (APIs) were assessed.  
1.2 Background Information 
HME is primarily utilized to improve the bioavailability of poorly-water soluble, 
crystalline active pharmaceutical ingredients (APIs) by dissolving them into water-soluble 
polymer excipients. At the same time, controlled-release oral dosages can be manufactured 
by dispersing water-soluble APIs into water-insoluble or swellable dissolution 
rate-controlling polymers (Terife et al., 2012). Combinations of the above can also be 
realized. Moreover, compared to traditional pharmaceutical processing methods, HME is 
appreciably less expensive manufacturing process and has the advantage of shorter and 
more efficient times to the final product through reduction of the processing steps involved 




Although HME and other pharmaceutical manufacturing methods utilize 
predominantly synthetic polymers as excipients, biopolymers or naturally occurring 
polymers constantly gain ground by virtue of renewability, biocompatibility and in some 
cases, biodegradability. The quest for a green technologies and the growing public 
awareness of climate changes stimulate the surging demand for green and renewable 
products with a low carbon foot-print. Moreover, the rapidly growing world population, 
aspires to a higher quality of life. Ultimately, this will lead to drastically increased demand 
for energy and resources. In this way, biopolymers play a prominent role (Mulhaupt, 
2014). They are made from renewable materials, and so do not use up fossil fuel resources 
and should result in fewer overall greenhouse gas emissions. And many of them are 
naturally biodegradable and so will not litter the environment after use (Evans, 2014). 
According to figure published last year by European Bioplastic, global biopolymer 
production capacity increased from 250,000 tons in 2009 to almost 1.4 million tons in 
2012, and is predicted to rocket to almost 6.2million tons by 2017. 
In this work, the possibility of using a sodium alginate, Keltone, as an excipient to 
manufacture oral dosage formulations with delayed release properties via HME are being 
explored. Sodium alginate is an anionic polysaccharide that is found in the cell walls of 
brown algae (Sperger et al., 2011). It is a linear co-polymer with homopolymeric blocks of 
(1-4)-linked β-D-mannuronate (M) and α-L-guluronate (G) covalently linked together in 
different sequence blocks. The monomers can appear in homopolymeric blocks of 
consecutive G-residues, consecutive M-residues or alternating M- and G-residues (Soares 
et al., 2004). Alginate is one of the most popular hydrogels and has been successfully 




commercial products containing ultrapure alginate (in accordance with GMP/ISO 9000 
guidelines) are extensively used as excipients in the pharmaceutical industry (Dornish et 
al., 2001). 
Keltone is a pH-depended solubility (insoluble in low pH, soluble in basic pH) 
material, which makes it a good candidate for intestinal drug delivery. Besides, Keltone is 
of high hydrophilicity biopolymer, which may play an important role in the targeting of 
gastrointestinal tissue in the development of orally administered drugs. Epithelial cells in 
gastrointestinal tissue are always covered by protective mucus. A feasible approach is to 
delay the transit through the gut, increasing the likelihood of contact between the delivery 
device and the tissue (Castro et al., 2008). By this way, Keltone can be a potential 
candidate of excipient for controlled-release drug. 
However, as a biopolymer, Keltone has two major drawbacks: Poor thermal 
properties (although crystalline, it has no practical melting point as it thermally degrades 
before it melts) and high water content that restrict it to a number of main applications. As 
a result, these properties can make it difficult to process the biopolymers into the final 
product. In this work, the possibility of using Keltone as an excipient to manufacture oral 
dosage formulations via HME was examined, in an effort to investigate the possibility of 




CHAPTER 2  
LITERATURE REVIEW   
2.1 Pharmaceutical Hot-melt Extrusion 
Hot-melt Extrusion (HME) is an emerging continuous processing technology for the 
development of various solid dosage forms and drug delivery systems. In the last few 
decades HME has attracted increased attention from both the pharmaceutical industry and 
academia. Pharmaceutical Hot-melt Extrusion (HME) is a term that the pharmaceutical 
sector adopted to differentiate it from traditional oral dosage producing techniques, such as 
direct compression and tableting. HME is primarily utilized to improve the bioavailability 
of poorly-water soluble active pharmaceutical ingredients (APIs) by dissolving them into 
water-soluble polymers. At the same time, its potential of manufacturing controlled-release 
oral dosages by dispersing water-soluble APIs into water-insoluble or rate-controlling 
polymers make it a promising technology in pharmaceutical industry.  
Due to its versatility in embracing a wide spectrum of applications, HME offers 
many advantages over conventional pharmaceutical production. HME is a solvent-free 
process, waiving the need for additional production stages (e.g., time-consuming drying 
steps), which also makes the process environmentally friendly. There exists a wide range 
of dosage forms which can be manufactured via HME (granules, pellets, tablets, films, 
sheets, rings, etc.), depending on the shape of the die and/or the post-processing technique 
(pelletizing, milling, calendering, injection molding, etc.). A uniform dispersion of API in 
the molten polymer result from the intense mixing and agitation imposed by the rotating 
screw during extrusion. The drug release profile offered by HME products via proper 




efficient approaching the delivery of Biopharmaceutics Classification System (BCS) class 
II compounds because of the improved absorption and therapeutic efficacy. On the other 
hand, HME is also an excellent tool to create sustained-release formulations when, for 
example, a hydrophobic polymer is extruded with a highly water-soluble drug. In this case, 
API is leached from the matrix much slower than compared to an equivalent compressed 
tablet (Gogos et al., 2012). 
The main drawback of HME is related to the thermal processing, limiting its 
application for thermo labile components. Degradation of the drug (API) and excipients 
may occur during HME because of high processing temperatures and heating due to 
viscous energy dissipation. However, changes in the configuration of the equipment (screw 
configuration, twin-screw extruders) or the addition of plasticizers can reduce process 
temperature and residence time to avoid thermal degradation during processing (Gogos et 
al., 2012). Additionally, there is a shelf-life stability concern arising from the 
thermodynamic tendency of the API to revert to its crystalline form at ambient 
temperatures. This will be resisted by the very low mobility of the dissolved API molecules 
in the Glassy excipient polymer matrix. 
HME involves the use of single or more commonly twin rotor extruders for the 
melting of usually water-soluble polymeric excipients, mixing them with APIs and 
pumping the homogeneous mixture through a die to form an extrudate. Processes of 
pharmaceutical HME can be classified into two categories. Case I, where the processing 
temperature is above the melting temperature (semi-crystalline polymer) or the glass 
Transition temperature of an amorphous polymer(Tg>50–100◦C) but below the melting 




glass transition temperature of semi-crystalline or amorphous polymers, respectively, and 
above the melting point of the API (Gogos et al., 2012). 
2.1.1 Elementary Polymer Processing Steps Taking Place in HME 
From a polymer processing perspective, HME involves five elementary steps: handling of 
particulate solids, melting, pressurization and pumping, mixing, and devolatilization and 
stripping (Tadmor and Gogos, 1979). For HME pharmaceutical processing, dissolution of 
the API in the molten excipient is an additional and most important elementary step, along 
with melting which precedes it and mixing which assists and speeds up dissolution. 
As co-rotating twin-screw extruders (co-TSEs) are more commonly used in HME 
process development and industrial practice, the following briefly reviewed features of the 
elementary steps of HME concern co-TSEs. 
2.1.1.1 Particulate Solids Handling (PSH). In co-rotating twin-screw extruders 
(co-TSEs), which are commonly used in HME process development, the particulate solid 
ingredients are fed gravimetrically or volumetrically controlled at constant rates. These 
rates are smaller than those needed to fully fill the parallel channels of the co-TSE, 
resulting in ‘starve-fed’ processing. Particulate solids handling in co-TSEs may result in 
spatial particle segregation if the relative sizes or shapes of the API and the excipient are 
very different, due to different air resistive forces and different particle/wall kinematic 
friction coefficients. It is also worth noting that polymer excipients are commonly 
hygroscopic, so they may have to be dried prior to dry mixing with the API particulates. 
2.1.1.2 Melting. The available melting mechanisms of co-TSEs are conductive melting of 




co-TSEs used in HME development, where the surface-to-volume ratio is large. However, 
for larger-diameter co-TSEs, reverse-screw or reverse-kneading elements are used to 
create a filled section in which the packed particulates undergo repeated volume-wide 
deformations before exiting the fully filled region. During this process, the very powerful 
melting mechanism of plastic energy dissipation (PED) is important and possibly 
dominant. It is also worth pointing out that the repeated large compressive deformations 
taking place in full kneading blocks generate heat by PED, but also induce 
particulate-to-particulate frictional heating and localized melting because of frictional 
energy dissipation (FED) (Tadmor, 2001) (Gogos, 1998). 
2.1.1.3 Devolatilization. Devolatilization refers to the removal of low levels of volatiles of 
the order of 1000 ppm, dissolved in the molten matrix. It is carried out in co-TSEs in 
partially filled sections isolated from both the upstream and downstream sections by ‘melt 
seals’ so that vacuum can be applied. Under vacuum conditions, the dissolved molecules 
cause bubbles to be formed in the flowing melt stream (much like the bubbles formed by 
opening a carbonated refreshment container) which, when they reach the melt–vacuum 
interface, burst and are removed (Tadmor and Gogos, 2006). 
2.1.1.4 Pumping and Pressurization. After the accomplishment of all the other 
elementary steps, the molten charge need to be pumped through a die which shapes the 
exiting streaming operations such as pelletization and sheet, film, tube or profiled 
cross-sectioned products. Drag-induced pumping and pressurization is the flow 
mechanism enabling both co-TSEs and SSEs to be the pumps of choice for viscous fluids. 




operations), they are ‘locked in’ with wide channels which are incapable of generating as 
high pumping pressures as single screw extruders, which can have shallow channels.  
2.1.1.5 Dispersive and Distributive Mixing. The mixing process in single- and 
twin-screw extruders, which is the most important elementary steps in the processes of 
HME, is generally categorized into two types: (a) dispersive mixing and (b) distributive 
mixing. 
Dispersive mixing refers to the process involving the particle size reduction of 
cohesive components such as solid fillers (by de-agglomeration) or liquid droplets (by 
droplet deformation and break-up). Distributive mixing refers to distributing 
de-agglomerated particulates uniformly throughout space, or stretching the interfacial area 
between the components lacking a cohesive resistance and distributing them uniformly 
throughout the product volume. Dispersive mixing is dictated by the magnitude of the 
laminar shear and extensional stresses and the type of flow generated by the processing 
equipment, whereas  distributive mixing is dictated only by the flow-generated strains. 
According to these definitions, the mixing of miscible liquids is regarded as distributive 
mixing, whereas mixing of hard solid agglomerates, immiscible liquids, and soft 
agglomerates is regarded as dispersive mixing (Tadmor and Gogos, 2006).The dispersive 






Figure 2.1  Dispersive mixing and distributive mixing of solid agglomerates and 
immiscible liquid droplets (Tadmor and Gogos, 2006). 
Source: Tadmor Z., Gogos C.G., 2006.Principles of Polymer Processing.2nd edition. Wiley-Interscience, 
New Jersey. 
2.1.2 Melting and Dissolution in Extrusion. 
In the process for pharmaceutical HME, dissolution of the API in the molten excipient is an 
additional and most important elementary step, along with melting and mixing. 
The physical mechanisms that can bring about melting or heating of any substance 
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The internal energy of a material can be raised by four sources as indicated in 













 )presents the net rate of internal energy increase per unit volume from an outside source 
by heat conduction;  (   )presents the (reversible) rate of internal energy increase per 
unit volume by compression; [ (    )]presents the (irreversible) rate of internal energy 
increase by flow and deformation; and Ṡ presents an additional possible homogeneous 
energy source.  
Melting of polymers is generally classified into conduction melting, compressive 
melting, deformation melting and homogeneous internal melting. Conduction melting is 
the most common mode, which raises the temperature of a solid and melts it. As the surface 
temperature of the solid is raised, a molten layer is formed and it grows with time. Thermal 
conductivity, attainable temperature gradients, and available contact area between the 
heating source and the melting solid are the rate-controlling factors of conduction melting. 
For polymers which have with low thermal conductivity and temperature 
sensitivity, the conduction melting is inefficient. However, in flood-fed single screw 
extruders, drag-induced melt removal takes place. The SSE quickly removes the freshly 
molten material from the vicinity of the high temperature zone, which reduces the risk of 
degradations. Also, it generates heat via viscous energy dissipation, which increases the 
efficiency of melting. 
Deformation melting involves irreversible conversion of mechanical energy to 
heat. It is significant, in viscous liquid, especially when the shear rates under processing 
condition are high. In the melting step of polymer processing, repeated deformation is 
imposed on a compacted bed of particulate solids, which generates significant, but 
non-homogeneous heat energy, called plastic energy dissipation (PED) and frictional 




deformations and generating heat within the particle and the mechanical energy dissipated 
into heat via inter-particle friction, separately. PED and FED play predominant role in 
processing equipment, in particular in co-rotating twin screw extruders (Co-TSEs). In this 
case, the thermal energy equation can be written as (Tadmor and Gogos, 2006): 
 
    
  
  
              
 
where   is the density of solid,    is specific heat of solid.      presents change of 
temperature. (    )  is rate of internal energy addition by conduction per unit volume. 
Since the fact that polymer solids and melts are virtually incompressible and other 
homogeneous internal melting, like dielectric heating, are limited in polymer processing 
practice, according to criteria of avoiding thermal degradation and achieving high 
processing rates, the melting mechanisms for polymers are summarized as: conduction 
melting with forced melt removal (by SSE), plastic energy dissipation (PED) and frictional 
energy dissipation (FED) (by twin rotor devices), and dissipative mix-melting (DMM) (by 
twin rotor co- and counter- rotating devices) (Tadmor and Gogos, 2006).  
Co-rotating twin screws with only conveying elements act similarly to single 
screw, which convey and compress the PM by a drag-induced mechanism, then melt by a 
drag-induced melt removal mechanism. However, because of their unique time-varying 
screw-to-screw interactions taking place, additional physical mechanisms emerge, which 
may primarily affect the elementary step of melting and mixing. In other configurations of 
TSEs, due to the addition mechanisms, melting and mixing steps are carried out more 





molten state. In SSEs, on the other hand, some of the polymer melts early in the extruder 
and some at the very end, and hence, the RTD in the molten state is rather broad. 
Melting in Co-TSEs with intense kneading blocks takes place primarily and most 
commonly in the kneading elements where particulates are fully compacted because of a 
flow restriction. The evolution of melting in such filled kneading-elementary channels was 
studied experimentally by Kim and Gogoset.al (Gogos et al., 1998). They found that 
inter-particles FED takes place early and does not require full compaction. At full 
compaction, PED becomes dominant melting mechanism. 
HME processes can be generally classified into two categories(Gogos et al., 
2012):Case I: in which the processing temperature is above the melting temperature 
(semi-crystalline polymer) or the softening temperature of an amorphous polymer 
(Tg>50–100◦C) but below the melting point of a crystalline API. Case II: in which the 
processing temperature is above both the melting or softening temperature of 
semi-crystalline or amorphous polymers, respectively, and above the melting point of the 
API. 
Case I provides a viable dissolution path which minimizes or circumvents the 
thermal degradation issue of drugs resulting in a desirable polymer-drug solid dispersion or 
solid solution, in which the solid API acts as a solute dispersion and the polymer excipient 
melt acts as a highly viscous solvent. On the other hand, it is expected that the dissolution 
rates and the solubility are larger in the case that the processing temperature is higher. 
Figure 2.2 shows its physical model schematically. 
The premixed drug (black) and polymer particles (white) are fed into the batch 




the mixer or extruder barrel and frictional and plastic energy dissipation for co-TSEs, 
leading to the solid drug particles being suspended in a continuous polymer melt matrices. 
While suspended at the processing temperature, which favors dissolution assuming 
intermolecular forces compatibility between the API and the excipient, the drug molecules 
start dissolving and create a mass-transfer boundary layer around each drug particles. This 
layer is continuously wiped away and replaced by fresh polymer melt around each API 
particulate by the laminar distributive flow of the mixer. The same laminar mixing flow 
helps the drug molecules to diffuse and mix distributively into the molten excipient. The 
size of suspended drug particles diminishes as the diffusion continues until the particles 
disappear and a homogeneous solution formed or until the limit of API solubility at the 
processing temperature is reached. In the latter case, they reach a minimum average size 
and remain suspended. The dissolution of the drug in the polymer melt in an extruder is 
achieved by laminar forced convective mass transfer involving the dissolving and 








Figure2.2  Schematic representation of the morphological changes of the drug and 
polymer system in the solution formation process (Case I). 
Source: C. G. Gogos, H. Liu and P. Wang, “Laminar Dispersive and Distributive Mixing with Dissolution 
and Applications to Hot Melt Extrusion”, Chapter 12 in Hot Melt Extrusion: Pharmaceutical Applications,D. 
Douroumis Ed., John Wiley and Sons Ltd, 2012 
 
The main task of Case I is to completely dissolve drugs in polymeric melt within 
the shortest possible residence time without raising the processed stream melt temperature. 
 Case II involves liquid – liquid mixing between miscible or partially miscible 





Figure 2.3  Schematic representation of the morphological changes of the drug and 
polymer system in the solution formation process (Case II). 
Source: C. G. Gogos, H. Liu and P. Wang, “Laminar Dispersive and Distributive Mixing with Dissolution 
and Applications to Hot Melt Extrusion”, Chapter 12 in Hot Melt Extrusion: Pharmaceutical Applications, D. 
Douroumis Ed., John Wiley and Sons Ltd, 2012 
 
The premixed drug (black) and polymer (white) particles are fed into an extruder 
and conveyed by the conveying elements. The polymer particles melt first due to the 
energy input from the barrel and frictional and plastic dissipation. After the polymer 
particles totally or partially melt, the drug particles suspended in the molten polymer melt 
rapidly, and the drug droplets begin to be deformed by the mixing laminar flows of the 
polymer melt rapidly, and the drug droplets begin to be deformed by the mixing laminar 
flows of the polymer melt. After that, the drug liquid phase breaks up into much smaller 
droplets due to the competition of surface tension and flow stress. The small droplets are 
deformed along the shear direction. With numerous very small droplets, which have an 
enormous surface, diffusion between the droplets and the polymer predominates causing 




Similarly to the dissolution of drugs in an aqueous medium, the dissolution of drug 
particulates in molten polymeric excipients during HME can also be described by the 
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where D is the diffusion coefficient; A is the total surface area of the drug exposed to the 
dissolution media; Cs is the saturation solubility of the drug in the liquid which (for 
HME)is the excipient melt; C describes the concentration of the dissolved solid phase in 
the bulk at time t; h represents the diffusion boundary layer at the solid-liquid interface; and 
V is the volume of the dissolution medium. The variables influencing the dissolution rate of 
drug particulates in the excipient melt can be grouped into three categories: process, 
equipment, and material. 
In both the diffusion and dissolution cases, the particle sizes of API in the molten 
excipient – API system play a significant role. The diffusion rate as well as the dissolution 
rate of drug particulates in polymer melt will increase if the total surface area of the drug 
particulates exposed to the dissolution media increase. Furthermore, the narrower the drug 
particle size distribution, the more uniform the total dissolution time distribution needed 
for complete dissolution of drugs in polymer melt will be (Gogos et al.,2012). 
2.2 Characterization Methods 
The objective of processing a formulation via HME is to transform thermoplastic materials 





formulation, the objective is to dissolve all or partial of the APIs into the polymeric 
excipient matrixes and fix the mas the amorphous form, then pump them through the die. In 
order to achieve these objectives, the materials require a substantial energy uptake which is 
provided by elevated temperatures, high shear forces and pressure to enable the intense 
mixing of drug and excipient during processing. To characterize the physical nature of 
extrudates at molecular or microscopic level, several methods can be used. An overview of 
the most common techniques for physicochemical characterization of HME-processed 
formulations is provided in the following sections. 
2.2.1 Thermo-analytical Methods 
Knowledge of the thermal behavior of the drug and polymers incorporated in the 
formulation is an essential aspect of dosage form development for HME, as product 
performance in terms of dissolution, bioavailability and stability highly depends on its 
thermal properties. 
The most common application of differential scanning calorimetry (DSC) for HME 
formulations is the assessment of drug crystallinity following HME processing and during 
storage, in order to determine its impact on drug release and bioavailability. In DSC tests, it 
is generally accepted that the absence of endothermic melting peak of the crystalline drug 
indicates that the drug is present in an amorphous rather than crystalline form. The crystal 
detection limitation of DSC is about 2% (Leuner, 2000). The DSC device maintains the 
same programmed temperature in each well and records the power required to achieve this. 
If a transition takes place in the sample, a characteristic excursion in the measured 




During development of an HME formulation, thermal analysis is essential to 
determinethe process conditions during HME, based on the thermal stability of the 
individual components as determined via differential scanning calorimetry (DSC) and/or 
thermal gravimetric analysis (TGA) . 
2.2.2 Microscopy 
Optical can help determine the existence of drug crystal regions and the size as well. 
Although the resolution of polarized light microscopy (PLM) is approximately at 1μm, the 
birefringence of the crystal drug imparts a sharp and distinct contrast against the 
amorphous (dark) excipient. Yoo et al. studied the miscibility/stability for 24 binary solid 
dispersion systems and found that the sensitivity to crystal detection was polarized light 
microscopy (PLM)> differential scanning calorimetry (DSC)>X- ray Diffraction(XRD) 
(Yoo, 2009). 
Hot stage microscopy (HSM) can be used to visualize the thermal events of sample 
formulations through a microscope during heating and/or cooling steps. Lloyd et al. found 
that HSM is far more sensitive to the presence of small quantities of solid drug than DSC 
(Lloyd, 1997) when studied the preparation of a solid dispersion of acetaminophen and 




CHAPTER 3  
MATERIALS AND METHODS 
3.1 Materials 
Keltone (LVCR) (FMC Biopolymer), A low viscosity anionic marine polysaccharide was 
used as a biopolymeric excipient (Figure3.1a). Diphenhydramine Hydrochloride (DMN) 
(BCS I) (Sigma Aldridge) (Figure3.1b) and Clotrimazole (CLO) (BCS II)(Sigma 
Aldridge) (Figure3.1c)were used as model APIs, respectively. Distilled water was used as 
a fugitive plasticizer for Keltone. In some experiments, Eudragit EPO (Figure3.1d) was 
used as a co-polymer/plasticizer for Keltone. The choice of DMN as API and water as 
plasticizer was due to earlier solvent casting experiments at Polymer Processing Institute 
(PPI) where it was showed that DMN forms solid solutions in Keltone in the presence of 
excess water. Further data to support the use of water as a plasticizer was the 
incompatibility (recrystallization) of polyethylene oxide (PEO) and the low boiling point 









Figure 3.1  Molecular structures of (a) Keltone (sodium alginate), (b) Diphenhydramine 
Hydrochloride, (c) Clotrimazole, (d) Eudragit EPO. 
 
3.2 Extrusion 
Extrusion was carried out in the Leistritz Nano16 Co-TSE (Leistritz). Figure 3.2 shows the 
appearance of Nano16 Co-TSE. Thisvery small laboratory extruder has two fully 
intermeshing, co-rotating, 16 mm in diameter screws equippped with neutral kneading 
blocks, which are shown in Figure 3.3. Nano16 Co-TSE has four heating barrel zones (3 
zones + die) while the temperature in the feeding zone can be controlled externally via a 







was fed to the extruder using the AccuRate 102M single-screw volumetric feeder (Schunck 
Corp). 
 
Figure 3.2  Overview of processing zones of Nano16 Co-TSE. 
 
 
Figure 3.3  Appearance of  the co-rotating screws. 
 
Water was injected at a constant rate via a siringe pump connected to zone I (after 
the feeding zone). The total feeding rate (Particulates and water) to the extruder was kept 






Physical mixtures of excipient and API were prepared by tumbler mixing at 50 rpm 
for one hour.  
3.3 Thermo Gravimetric Analysis (TGA) 
The Perkin Elmer Thermogravimetric Analysis 7 was used in this work. The ramp mode 
was used to determine the water content of Keltone and residual water content of the 
extrudates. The samples were placed in an aluminum pan and heated from 30C to 250C 
at a heating rate of 10C/min under air. Preliminary experiments in the TGA under both air 
and nitrogen atmospheres, showed that the degradation of Keltone and its physical 
mixtures (PMs) is thermal so there was no need for a nitrogen blanket during processing.  
Isothermal mode was used to determine the stability of the materials at the processing 
temperature. In isothermal heating tests, powders were quickly heated to 150C at a rate of 
40C/min and held isothermally for 10 minutes. 
3.4 Differential Scanning Calorimetry (DSC) 
The thermal transitions of raw materials, PMs and extrudates during heating were 
determined using a Metler Toledo Polymer DSC. 
 
3.5 Hot-Stage, Polarized Light Microscopy (PLM) 
A hot stage (Mettler FP90) was used in conjunction with a Carl Zeiss microscope 
(Thornwood, NY)to observe morphology evolution of extrudate samples under polarized 





CHAPTER 4  
RESULTS AND DISCUSSION 
4.1 Background 
Previous work at PPI had showed that (a) Keltone could not be extruded by itself unless a 
plasticizer (PEO in this case) was added. In addition it was found that Indomethacin (IND) 
could not be dissolved in Keltone by itself. It may be a result from that both Keltone and 
IND are anionic materials. IND was found to dissolve in a formulation with both Keltone 
and PEO, however the product was found to be unstable following extrusion (both PEO 
and IND recrystallized). To determine if the dissolution ability of Keltone is related to its 
charge, we used Diphenhydramine Hydrochloride (DMN), which is a cationic drug. Based 
on literature(M. Pavli et al., 2009), anionic polymers like carrageenans (very similar in 
structure to sodium alginates) can form solid solutions with cationic drugs by solvent 
casting in excess of water. To further investigate the ability of Keltone to form ionic 
complexes with oppositely charged molecules, Eudragit EPO, a cationic polymer was used 





Figure 4.1  Ramp heating of DMN, Keltone, Keltone/DMN PM and Keltone/DMN 
solvent-casted film. 
 
Figure 4.1 shows the DSC ramp heating of Keltone/DMN 50:50 PM and solvent 
casted film as well as of the raw materials of this formulation. The endothermic enthalpy of 
DMN in the PM is very close to the melting enthalpy of the pure drug suggesting the 
absence of any interaction between the two components (black tracer). However, when the 
solvent-casted film was heated there is a very small endotherm (~2 J/g) ~10°C lower than 
the melting point of pure DMN that may be related to the dissolution of DMN in 
KELTONE (blue tracer). The above strongly suggest that ~50% of DMN was dissolved in 





4.2 Characterization of Raw Materials 
The thermal properties and morphologies of the raw materials were characterized in this 
Section. The characteristic thermal transition temperature of Keltone, Eudragit EPO, DMN 
and CLO are presented in Figures 4.1 and 4.2. DSC was used to get characteristic thermal 
transition temperatures, including the glass transition temperature of Eudragit EPO, the 
melting temperature of DMN and CLO. 
 
Figure 4.2  Heat-cool-heat scan of Keltone and Eudragit EPO, ramp heating of CLO. 
 
The melting point of DMN is ~ 171°C whereas Clotrimazolemelts~145°C. The Tg 
of EPO form the second heating is ~ 46°C.Keltone lacks any characteristics transition in 
the temperature range examined in this work. The large endotherm during the first heating 




The TGA ramp and isothermal heating as well as thermal stability based on color 
change of Keltone are presented in Figure 4.3 The onset temperature of weight loss in the 
TGA ramp heating tests is above 200C. This test was also conducted under N2 to 
determine whether the degradation was oxidative in nature. Since no difference between 
the two ramp tests was detected, there is no need to process Keltone under N2. The 
isothermal TGA was conducted to further examine the thermal stability a function of time. 
The isothermal TGA at the HME barrel temperature (150C) was conducted to further 
examine the thermal stability of CLO, as shown in Figure 4.4.The sample was processed 

















Figure 4.3  (a)Ramp heating of Keltone under air, (b) isothermal heating for 10 min,  
(c) degradation-induced color change relative to the original material. 
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Figure 4.4  Isothermal heating of CLO for 10 min (vertical/ horizontal axes: weight / time). 
4.3 Extrusion 
In this section, the possibility of Keltone being extruded with water as a plasticizer and 
DMN as an API was examined. We also extruded Keltone with EPO as a plasticizer and 
Clotrimazoleas an API. The minimum amount of plasticizer and the processing 
temperature of Keltone were optimized. TGA tests were conducted to identify the residual 
water content of extrudates. DSC tests were conducted to determine the thermal transitions 
of extrudates during heating. 
4.3.1 Optimization of Minimum Amount of Plasticizer and Processing Temperature 
for Keltone Using Water as Plasticizer 
 
Extrusion optimization runs were performed to identify a) the minimum concentration of 
water as a plasticizer for Keltone and b) the optimum extrusion temperature. Table 4.1 lists 




first three combinations (Formulations #1 to #3) of composition/processing temperature 
resulted into extrudates of acceptable consistency and ease of extrusion. Extrusion of 
formulation #4 was very unstable and resulted into an extrudate of uneven consistency, 
because of a combination of high temperature and low water content. Formulation #5 could 
not be extruded as the amount of water was too low (blockage of the extruder). Based on 
the preliminary runs without API we decided that the most suitable extruder barrel 
temperature profile is the following: 120°,   90° ,  80°,   80° ,  50°C; the die temperature in 
the range of 124-126°C; and the minimum amount of water as plasticizer allowing 
extrusion runs is 40%. Formulations #6 and #7 were the two formulations that contained 
DMN, based on 40% of water as plasticizer. Formulation #6 was not possible to extrude. 
Formulation #7 was also very difficult to extrude and had very low viscosity (oil-like). 





Figure 4.5  Appearance of extrudates after extrusion: (a) formulation #1, (b) formulation 
#2, (c) formulation #3, (d) formulation #4 and (e) formulation #7 (after drying). 






              Table 4.1   Formulations and Extrusion Conditionsof Keltone, DMN And Water 




(Keltone/DMN/total water) (%(w/w)) 
(C°) 
M   Z4(D)   Z3   Z2   Z1 Z0(F) 
  
(adjusted for Keltone water content 
(~15%)) 
 
1 42.9/-/57.1 36.1/-/63.9 126°   120°   90°   80°   80°   50° 
2 42.9/-/57.1 36.1/-/63.9   124°   130°   100°   80°   80°   50° 
3 60/-/40 50.5/-/49.5 125°   120°   90°   80°   80°   50° 
4 60/-/40 50.5/-/49.5   126°   130°   100°   80°   80°   50° 
5 66.7/-/33.3 56.7/-/43.3 129°   120°   90°   80°   80°   50° 
    
6 42/30/28 35.7/30/34.3 126°   120°   90°   80°   80°   50° 









Figure 4.6  Torque, pressure, and melt temperature traces for extrudate #1. 
 
Figure 4.7  Torque, pressure, and melt temperature traces for extrudate #2. 
 
Figure 4.8  Torque, pressure, and melt temperature traces for extrudate #3. 
 
Figure 4.9  Torque, pressure, and melt temperature traces for extrudate #4. 
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K/-/W: 42.9/-/57.1 (w/w) - LT 
K/-/W: 42.9/-/57.1 (w/w) - HT 
K/-/W: 60/-/40 (w/w) - LT 





Figure 4.10  Torque, pressure, and melt temperature traces for formulation #5. 
 
 
Figure 4.11  Torque, pressure, and melt temperature traces for formulation #6. 
 
 
Figure 4.12  Torque, pressure, and melt temperature traces for formulation #7. 
 
 
Figures4.6-4.12 show the torque, die pressure and melt temperature during 
extrusion of formulations #1-#6. In all graphs the torque and die pressure are unstable. 
This is probably a result of the fact that the incorporation of water into Keltone is taking 
much of the extruder length to complete. Therefore, most of the extruder barrel is filled 
with what may be mostly a “wet powder” mixture, while true dissolution of Keltone into 
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water takes place only at the end of the barrel. Including additional kneading elements in 
the extruder screw to enhance early and adequate mixing of the feed, primarily water 
incorporation, maybe a way to circumvent torque and die pressure instabilities. 
4.3.2 Thermo-Gravimetric Analysis of Extruded Formulations 
Water or moisture is undesirable in finished pharmaceutical products since its presence 
can result in product instabilities (e.g., recrystallization of drug, change of mechanical 
properties of tablets). For this reason, after extrusion, TGA was used to determine the 
residual water content of extrudates #1, #2, #3, #4 and #7. For ramp heating, a heating 
rate of 10°C/min was used to heat the samples from 30°C to 250°C. Runs were 
occasionally performed in duplicate with good reproducibility. 
From the results in Figure 4.13 it can be seen that the more water the formulation 
initially contains, the more water the extrudates contain. In addition, for the same 
formulation composition, the higher the extrusion temperature, the less water the 
extrudates contain. For lower initial water contents (formulation #3 and #4) increasing 
the temperature by 10°C at the last two zones of the extruder can result in a ~15% 
reduction in residual water (36% vs 21%). It should be noted that when we attempted to 
use higher die temperatures (>130°C) to remove all or most of the water at the end of the 
barrel, the extruder was blocked. This is due to the fact that Keltone and related 
polysaccharides are crystalline polymers that do not possess a practical melting point 





Figure 4.13  TGA ramp heating of pure Keltone, DMN and extruded formulations #1-#4 
and #7. 
4.3.3 Concluding Remarks 
The processability of Keltone extruding with water as a plasticizer was explored. The 
most suitable extruder temperature profile along the extruder barrel and die (from the 
screw tip to the hopper)for Keltone using water as a plasticizer is the following: 120° ,  
90° ,  80° ,  80°,   50°C, the minimum amount of water as plasticizer allowing extrusion 
runs is 40%. The residual water contents in extrudate were determined by TGA test, 
which show that the residual water contents in extrudates were from 21% to 48%. Higher 





4.3.4 Optimization of Amount of Plasticizer and Processing Temperature of 
Keltone Using Eudragit EPO as Plasticizer 
 
In this section, extrusion optimization runs were performed to identify a) the optimum 
amount of Eudragit EPO as a plasticizer for Keltone and b) the optimum extrusion 
temperature. Table 4.2 lists the barrel temperatures and compositions used during all 
extrusion optimmzation runs.The first three combinations (Formulations #1 to #3) of 
composition/processing temperature could not be extruded as the amount of Eudragit 
EPO was too low (blockage of the extruder) and the processing temperature was too low 
(materials seem to consolidate). Formulation #4 was succesfully extruded and with ease. 
However considerable discoloration was observed potentially as a result of thermal 
degradation. By lowering the processing temperature and increasing the amount of 
EPO,formulation #5 produced an extrudate with color closer to the original raw 
materials. Based onpreliminary runs without API, the most suitable extruder temperature 
profile of Keltone with Eudragit EPO as plasticizer was decidedas the following: 150°   
150°   130°   80°   50°C. Control formulation #6 containedonly Eudragit EPO and CLO. 
Formulation #7 and #8 were the two formulations that contained Keltone, Eudragit EPO 
and CLO, using the same ratio of EPO/CLO as in formulation #6. Both of the two runs 
were of good consistency and were easily extruded. Figure 4.14 shows the appearance of 








Table 4.2Formulationsand Extrusion Conditions of Keltone, CLO and Water 





M   Z4(D)   Z3   Z2   Z1 Z0(F) 
   
1 90/-/10  145°   130°   100°   80°   80°   50° 
2 85/-/15  165°   130°   100°   80°   80°   50° 
3 70/-/30 161°   150°   140°   120°   80°   50° 
4 50/-/50 166°   160°   160°140°   80°   50° 
5 40/-/60 159°   150°   150°130°   80°   50° 
   








157°   150°   150°   130°   130°   50 





Figure 4.14  Appearance of extrudates after extrusion: (a) formulation #4, (b) 













Figure 4.15  Torque, melt temperature traces for formulation #1. 
 
Figure 4.16  Torque, melt temperature traces for formulation #2. 
 
Figure 4.17  Torque, melt temperature traces for formulation #3. 
 
Figure 4.18  Torque, melt temperature traces for formulation #4. 
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Figure 4.19  Torque, melt temperature traces for formulation #5. 
 
Figure 4.20  Torque, melt temperature traces for formulation #6. 
 
Figure 4.21  Torque, melt temperature traces for formulation #7. 
 
Figure 4.22  Torque, melt temperature traces for formulation #8. 
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Figures 4.15-4.22 show the torque and melt temperature during extrusion of 
formulations #1-#8. In Figures 4.15-4.17the torque is unstable. This maybe a result of the 
fact of the insufficient amount of Eudragit EPO as a plasticizer. In Figures 4.18-4.22, the 
torque of during extrusion of formulation #4-#8 is of acceptable stability, due to the good 
consistency of formulation component homogenization during the extrusion. 
4.3.5 Observation on Hot Stage Microscopy 
Figure 4.23  Transmission optical microscopy evolutions of EPO/CLO/Keltone 










A hot stage was used to observe the morphology evolution in conjunction with the optical 
microscope. Figures 4.19- 4.20 show themorphology evolution of extrudate #7and 
extrudate #8at the same heating rates, which was set 20C/min from 30 to 160 C, 
conducted on a hot stage microscope. No changes in shapes of the crystals were shown in 
their morphologies during heating. Since the final temperature is beyond the melting 
point of CLO, which is 146C, the crystals seen in these images are crystalline Keltone, 





4.3.6 Differential Scanning Calorimetry Analysis of Extruded Formulation 
 
Figure 4.25  Ramp heating of EPO/CLO PM and extrudate. 
 




Figure 4.25 shows the ramp heating of EPO/CLO 70/30 PM and extrudates that was used 
as a control for the EPO/CLO/KEL formulations. During the heating of the PM there is 
an endotherm that corresponds to the dissolution of CLO into EPO. During the heating of 
the extrudate, there is no endotherm indicating that 30% CLO is dissolved into EPO. In 
addition no traces of crystalline drug were found when looked at the extrudate under the 
polarized light microscope (results not shown). 
Figure 4.26 shows the ramp heating of the PMs and extrudates of the two 
formulations with EPO, CLO and KEL. The dissolution endotherm of the CLO in the 
extrudate with 10% Keltone is larger that the one with 20% Keltone since the former 
contains more CLO. However, both of the extrudates show no dissolution endotherm for 
CLO (there is a very small endotherm in the extrudate with 10% Keltone however, the 
value of 0.3 J/g is extremly small to be taken as indication of undissolved CLO). These 
results correlate with the absence of any CLO crystals in the PLM images of the 
extrudates (Figures 4.23 and 4.24). The uncosolidated Keltone seen in these PLM images 
cannot be detected by the DSC as Keltone lacks any characteristic thermal transitions in 






CHAPTER 5  
SUMMARY AND FUTURE WORK 
 
The work in this thesis has focused on the assessment of the possibility of using Keltone, 
a marine polysaccharide derived from brown seaweed, as a polymeric excipient for 
pharmaceutical HME. Water and Eudragit EPO were used as plasticizers, and 
Diphenhydramine Hydrochloride and Clotrimazole were used as active pharmaceutical 
ingredients (APIs). Extrusion was conducted in the Leistritz Nano16 Co-TSE.TGA was 
used to determineresidual water content of the extrudates. DSC was used to characterize 
thermal transitions of extrudates during heating. Optical microscopy was used to 
determine any undissolved API. 
In this work, the minimum amount of plasticizer and processing temperature for 
Keltone using water as plasticizer was optimized. The most suitable extruder temperature 
profiles is: 120°   90°   80°   80°   50°C, while the minimum amount of water as plasticizer 
allowing extrusion runs is 40%.Above a certain processing temperature and below a 
certain amount of water, extrusion of Keltone was not possible. Based on above 
formulation of Keltone and water, and the suitable processing temperature, extrusions 
contained DMN were conducted. However, formulation contained DMN could not be 
extruded in consistency. DMN does not dissolve in the extrudates when heated in DSC, 
therefore water may play a very important role in this. In the TGA result of the samples 
extruded using the mos suitable conditions, the residual water is 21%. As water or 




instabilities, water may not be a proper candidate as plasticizer for the extrusion of 
Keltone. 
The processability of Keltone by extrusion using Eudragit EPO was also assessed 
in this work. The most suitable extruder temperature profiles was: 150°   150°   130°   80°   
50°C, and the optimal amount of Eudragit EPO was found to be 60% wt. Formulations 
contained CLO as API were extruded under this condition. The DSC analysis of the 
extrudates showed no melting peak for CLO, suggesting that this drug only can fully 
dissolve in the excipient matrix in an amorphous state.  
An important summary conclusion is the following: as a result of this work we 
can state with certainty that Keltone cannot be easily or widely used as polymer 
excipient. 
Future work can be done as follows:  
The plasticizer being used is distilled water with a specific pH of four. As Keltone 
is insoluble in acidic pH and soluble in basic pH, the pH of distilled water can be adjusted 
to higher one, in which way Keltone may be processed more easily. The combination of 
water and Eudragit EPO as a plasticizer also has the potential to allow the extrusion of 
Keltone. 
Clotrimazole (CLO) is a weak base with two ionizable nitrogen atoms, which 
may make CLO exhibit good dissolution behavior under acidic conditions in stomach, 
but is likely to precipitate further in gastrointestinal tract because of a sharp increase in 
pH under the condition found in the intestine. This may result in poor and erratic 
bioavailability. Since the DSC result of extrudates showed that CLO was fully dissolved 




Keltone is a pH-depended solubility (insoluble in low pH, soluble in basic pH) material, 
which makes it a good candidate of excipient for target-release of CLO. Further work of 
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